|
Greiner, J W; Guadagni, F; Goldstein, D et al. (1992) Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 10:735-46
|
|
Hank, J A; Weil-Hillman, G; Surfus, J E et al. (1990) Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother 31:53-9
|
|
Witt, P L; Spear, G T; Helgeson, D O et al. (1990) Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages. J Interferon Res 10:393-402
|
|
Hank, J A; Sosman, J A; Kohler, P C et al. (1990) Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. J Biol Response Mod 9:5-14
|
|
Schiller, J H; Storer, B; Paulnock, D M et al. (1990) A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest 86:1211-21
|
|
Kohler, P C; Hank, J A; Moore, K H et al. (1989) Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion. Cancer Invest 7:213-23
|
|
Hank, J A; Kohler, P C; Weil-Hillman, G et al. (1988) In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res 48:1965-71
|
|
Rosenthal, N S; Hank, J A; Kohler, P C et al. (1988) The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. J Biol Response Mod 7:123-39
|
|
Sondel, P M; Kohler, P C; Hank, J A et al. (1988) Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 48:2561-7
|
|
Sondel, P M; Hank, J A; Rosenthal, N et al. (1987) Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC). Prog Clin Biol Res 244:173-84
|
